| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plaque, Atherosclerotic | 95 | 2024 | 1551 | 6.830 |
Why?
|
| Tomography, Optical Coherence | 107 | 2024 | 2957 | 4.200 |
Why?
|
| Coronary Vessels | 80 | 2024 | 3124 | 3.810 |
Why?
|
| Acute Coronary Syndrome | 59 | 2024 | 2194 | 3.540 |
Why?
|
| Coronary Artery Disease | 78 | 2024 | 6568 | 3.090 |
Why?
|
| Teriparatide | 20 | 2022 | 226 | 2.230 |
Why?
|
| Coronary Angiography | 81 | 2024 | 4541 | 2.100 |
Why?
|
| Bone Density | 56 | 2024 | 3573 | 2.100 |
Why?
|
| Bone Density Conservation Agents | 23 | 2024 | 797 | 1.960 |
Why?
|
| Osteoporosis, Postmenopausal | 14 | 2024 | 399 | 1.870 |
Why?
|
| Coronary Thrombosis | 10 | 2021 | 440 | 1.060 |
Why?
|
| Ultrasonography, Interventional | 19 | 2023 | 1523 | 0.910 |
Why?
|
| Amenorrhea | 10 | 2018 | 484 | 0.910 |
Why?
|
| Predictive Value of Tests | 53 | 2024 | 15454 | 0.770 |
Why?
|
| Students | 13 | 2009 | 1744 | 0.750 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2020 | 3251 | 0.730 |
Why?
|
| Growth Hormone-Releasing Hormone | 5 | 2024 | 128 | 0.730 |
Why?
|
| Bone and Bones | 15 | 2024 | 2589 | 0.720 |
Why?
|
| Middle Aged | 254 | 2024 | 223492 | 0.720 |
Why?
|
| Alendronate | 8 | 2024 | 174 | 0.700 |
Why?
|
| Athletes | 12 | 2024 | 1162 | 0.690 |
Why?
|
| Testosterone | 17 | 2020 | 2491 | 0.680 |
Why?
|
| Female | 318 | 2024 | 397192 | 0.680 |
Why?
|
| Body Composition | 23 | 2024 | 2462 | 0.680 |
Why?
|
| Universities | 9 | 2009 | 1005 | 0.670 |
Why?
|
| Humans | 411 | 2024 | 768166 | 0.610 |
Why?
|
| Coronary Stenosis | 8 | 2021 | 802 | 0.600 |
Why?
|
| Male | 257 | 2024 | 364719 | 0.580 |
Why?
|
| Gonadotropin-Releasing Hormone | 11 | 2021 | 1149 | 0.570 |
Why?
|
| Aged | 170 | 2024 | 171504 | 0.570 |
Why?
|
| Drug-Eluting Stents | 8 | 2017 | 681 | 0.560 |
Why?
|
| Lipids | 20 | 2024 | 3343 | 0.560 |
Why?
|
| Bone Remodeling | 12 | 2024 | 583 | 0.550 |
Why?
|
| Rupture, Spontaneous | 14 | 2024 | 365 | 0.550 |
Why?
|
| Postmenopause | 9 | 2024 | 2518 | 0.540 |
Why?
|
| Myocardial Infarction | 18 | 2024 | 11519 | 0.520 |
Why?
|
| Absorptiometry, Photon | 23 | 2024 | 1758 | 0.520 |
Why?
|
| Atherosclerosis | 12 | 2024 | 3433 | 0.510 |
Why?
|
| HIV Infections | 27 | 2024 | 17569 | 0.510 |
Why?
|
| Ovarian Neoplasms | 21 | 2020 | 4916 | 0.510 |
Why?
|
| Alcohol Drinking | 10 | 2009 | 4045 | 0.500 |
Why?
|
| Anorexia Nervosa | 8 | 2018 | 1364 | 0.490 |
Why?
|
| Chest Pain | 8 | 2015 | 1101 | 0.470 |
Why?
|
| Goserelin | 4 | 2020 | 126 | 0.460 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 6 | 2017 | 704 | 0.450 |
Why?
|
| Adult | 174 | 2024 | 223646 | 0.440 |
Why?
|
| Radius | 9 | 2024 | 443 | 0.430 |
Why?
|
| Coronary Circulation | 6 | 2021 | 1617 | 0.420 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2024 | 742 | 0.420 |
Why?
|
| Estrone | 3 | 2023 | 234 | 0.410 |
Why?
|
| Mixed Tumor, Mullerian | 6 | 2009 | 55 | 0.390 |
Why?
|
| Neointima | 6 | 2015 | 133 | 0.390 |
Why?
|
| Treatment Outcome | 77 | 2024 | 65371 | 0.380 |
Why?
|
| Fibroblast Growth Factors | 7 | 2015 | 873 | 0.380 |
Why?
|
| Osteoporosis | 10 | 2017 | 1605 | 0.370 |
Why?
|
| Estradiol | 9 | 2019 | 1951 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 11878 | 0.350 |
Why?
|
| Gastrectomy | 6 | 2024 | 693 | 0.350 |
Why?
|
| Tibia | 8 | 2024 | 1076 | 0.350 |
Why?
|
| Nerve Fibers | 3 | 2024 | 709 | 0.340 |
Why?
|
| Adipose Tissue | 9 | 2024 | 3329 | 0.340 |
Why?
|
| Retrospective Studies | 69 | 2024 | 81762 | 0.330 |
Why?
|
| Fibrinolytic Agents | 6 | 2021 | 2080 | 0.330 |
Why?
|
| Alcoholic Intoxication | 3 | 2009 | 171 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2024 | 9419 | 0.320 |
Why?
|
| Kidney Transplantation | 5 | 2023 | 4262 | 0.320 |
Why?
|
| Obesity, Morbid | 3 | 2024 | 1298 | 0.310 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 536 | 0.310 |
Why?
|
| Diphosphonates | 3 | 2024 | 634 | 0.310 |
Why?
|
| Arteritis | 2 | 2024 | 159 | 0.310 |
Why?
|
| Staphylococcal Infections | 5 | 2016 | 1398 | 0.300 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2019 | 1209 | 0.300 |
Why?
|
| Oligomenorrhea | 2 | 2019 | 42 | 0.300 |
Why?
|
| Oxytocin | 2 | 2023 | 404 | 0.300 |
Why?
|
| Young Adult | 53 | 2024 | 60066 | 0.300 |
Why?
|
| Retinal Ganglion Cells | 3 | 2024 | 811 | 0.290 |
Why?
|
| Time Factors | 46 | 2024 | 40218 | 0.290 |
Why?
|
| Bone Resorption | 4 | 2019 | 728 | 0.290 |
Why?
|
| Fractures, Bone | 7 | 2023 | 2062 | 0.290 |
Why?
|
| Stents | 12 | 2022 | 3195 | 0.290 |
Why?
|
| Mammary Arteries | 2 | 2024 | 82 | 0.290 |
Why?
|
| Phacoemulsification | 2 | 2019 | 151 | 0.290 |
Why?
|
| Imidazoles | 3 | 2024 | 1169 | 0.290 |
Why?
|
| Adolescent | 69 | 2024 | 89169 | 0.290 |
Why?
|
| Glaucoma, Angle-Closure | 2 | 2019 | 192 | 0.280 |
Why?
|
| Cross Infection | 6 | 2018 | 1426 | 0.280 |
Why?
|
| Calcinosis | 4 | 2022 | 1481 | 0.280 |
Why?
|
| Coronary Restenosis | 3 | 2015 | 396 | 0.280 |
Why?
|
| Sirolimus | 6 | 2022 | 1540 | 0.280 |
Why?
|
| Drug Administration Schedule | 13 | 2024 | 4860 | 0.270 |
Why?
|
| Human Growth Hormone | 4 | 2020 | 651 | 0.270 |
Why?
|
| Follow-Up Studies | 37 | 2024 | 39348 | 0.270 |
Why?
|
| Libido | 2 | 2020 | 124 | 0.270 |
Why?
|
| Adiposity | 5 | 2020 | 1895 | 0.270 |
Why?
|
| Starvation | 2 | 2018 | 141 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2024 | 20760 | 0.270 |
Why?
|
| Endothelium, Vascular | 4 | 2021 | 4427 | 0.270 |
Why?
|
| Transplantation Chimera | 2 | 2019 | 594 | 0.270 |
Why?
|
| Transplantation Tolerance | 3 | 2023 | 633 | 0.260 |
Why?
|
| Optic Nerve Diseases | 2 | 2024 | 342 | 0.260 |
Why?
|
| Aging | 8 | 2024 | 8744 | 0.250 |
Why?
|
| Williams Syndrome | 2 | 2018 | 195 | 0.250 |
Why?
|
| Optic Disk | 2 | 2024 | 421 | 0.250 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2014 | 727 | 0.250 |
Why?
|
| Aromatase | 1 | 2005 | 147 | 0.250 |
Why?
|
| Infection Control | 4 | 2017 | 985 | 0.250 |
Why?
|
| Prevalence | 24 | 2024 | 15869 | 0.240 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2020 | 2043 | 0.240 |
Why?
|
| Fibrosis | 12 | 2024 | 2080 | 0.240 |
Why?
|
| Risk Factors | 56 | 2024 | 74944 | 0.240 |
Why?
|
| Hip Fractures | 2 | 2024 | 997 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 6 | 2016 | 2631 | 0.240 |
Why?
|
| Brachytherapy | 2 | 2009 | 1220 | 0.240 |
Why?
|
| Fasting | 3 | 2021 | 1610 | 0.240 |
Why?
|
| Prognosis | 24 | 2024 | 30010 | 0.240 |
Why?
|
| Placebos | 5 | 2024 | 1667 | 0.230 |
Why?
|
| Diabetic Angiopathies | 3 | 2015 | 806 | 0.230 |
Why?
|
| Cholesterol, LDL | 6 | 2020 | 2403 | 0.230 |
Why?
|
| Infertility | 2 | 2023 | 655 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 1757 | 0.230 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2014 | 489 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 4058 | 0.230 |
Why?
|
| Hyperthyroidism | 2 | 2023 | 292 | 0.220 |
Why?
|
| Enterococcus | 2 | 2017 | 159 | 0.220 |
Why?
|
| Intraocular Pressure | 4 | 2024 | 1304 | 0.220 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 6395 | 0.220 |
Why?
|
| Hospitals, General | 3 | 2017 | 809 | 0.220 |
Why?
|
| Visual Field Tests | 2 | 2024 | 415 | 0.220 |
Why?
|
| Lipid Metabolism | 5 | 2018 | 1904 | 0.220 |
Why?
|
| Parathyroid Hormone | 3 | 2008 | 1804 | 0.220 |
Why?
|
| Cystic Fibrosis | 2 | 2023 | 1294 | 0.220 |
Why?
|
| Models, Cardiovascular | 3 | 2021 | 981 | 0.210 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2021 | 1024 | 0.210 |
Why?
|
| Drug Therapy, Combination | 14 | 2020 | 6316 | 0.210 |
Why?
|
| Sex Characteristics | 4 | 2024 | 2650 | 0.210 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2017 | 538 | 0.210 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2019 | 1536 | 0.210 |
Why?
|
| Opiate Alkaloids | 1 | 2023 | 27 | 0.210 |
Why?
|
| Ghrelin | 2 | 2022 | 251 | 0.210 |
Why?
|
| Visual Fields | 2 | 2024 | 1065 | 0.210 |
Why?
|
| Aged, 80 and over | 42 | 2024 | 59629 | 0.210 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2023 | 267 | 0.210 |
Why?
|
| Pituitary Diseases | 1 | 2023 | 137 | 0.200 |
Why?
|
| Blood Glucose | 10 | 2024 | 6430 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2021 | 1942 | 0.200 |
Why?
|
| Bariatric Surgery | 2 | 2024 | 1001 | 0.200 |
Why?
|
| Insulin Resistance | 5 | 2023 | 3986 | 0.200 |
Why?
|
| Serpins | 1 | 2024 | 246 | 0.200 |
Why?
|
| Bacteriological Techniques | 2 | 2014 | 277 | 0.200 |
Why?
|
| Registries | 19 | 2020 | 8375 | 0.200 |
Why?
|
| Subcutaneous Fat | 3 | 2017 | 404 | 0.200 |
Why?
|
| Diabetes Mellitus | 5 | 2024 | 5889 | 0.200 |
Why?
|
| Obesity | 10 | 2023 | 13090 | 0.190 |
Why?
|
| Social Problems | 1 | 2002 | 108 | 0.190 |
Why?
|
| Inflammation | 13 | 2024 | 10873 | 0.190 |
Why?
|
| Prospective Studies | 34 | 2024 | 54926 | 0.190 |
Why?
|
| Neoplasm Staging | 11 | 2024 | 11244 | 0.190 |
Why?
|
| Myocardial Revascularization | 5 | 2020 | 795 | 0.190 |
Why?
|
| Anticholesteremic Agents | 3 | 2018 | 972 | 0.190 |
Why?
|
| Marketing | 1 | 2003 | 224 | 0.190 |
Why?
|
| Aromatase Inhibitors | 5 | 2019 | 519 | 0.190 |
Why?
|
| Hypolipidemic Agents | 2 | 2015 | 609 | 0.180 |
Why?
|
| Anthozoa | 1 | 2021 | 65 | 0.180 |
Why?
|
| Hypogonadism | 5 | 2009 | 805 | 0.180 |
Why?
|
| Angiotensins | 2 | 2022 | 141 | 0.180 |
Why?
|
| Massachusetts | 14 | 2021 | 8890 | 0.180 |
Why?
|
| Angina Pectoris | 3 | 2015 | 957 | 0.180 |
Why?
|
| Leuprolide | 3 | 2008 | 313 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2024 | 4063 | 0.180 |
Why?
|
| Reproducibility of Results | 23 | 2024 | 20227 | 0.180 |
Why?
|
| Double-Blind Method | 16 | 2024 | 12465 | 0.180 |
Why?
|
| Heparin | 2 | 2021 | 1636 | 0.180 |
Why?
|
| Growth Hormone | 3 | 2020 | 573 | 0.180 |
Why?
|
| Infertility, Male | 1 | 2023 | 397 | 0.180 |
Why?
|
| Thyrotropin | 3 | 2023 | 834 | 0.180 |
Why?
|
| Ethanol | 3 | 2009 | 1331 | 0.180 |
Why?
|
| Dwarfism, Pituitary | 1 | 2020 | 39 | 0.180 |
Why?
|
| Bone Marrow | 2 | 2021 | 2935 | 0.170 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 1640 | 0.170 |
Why?
|
| Chi-Square Distribution | 10 | 2017 | 3436 | 0.170 |
Why?
|
| Blood Donors | 6 | 2011 | 343 | 0.170 |
Why?
|
| Peptide Fragments | 6 | 2019 | 5151 | 0.170 |
Why?
|
| Pelvic Bones | 1 | 2022 | 274 | 0.170 |
Why?
|
| Adaptation, Physiological | 2 | 2018 | 1312 | 0.170 |
Why?
|
| Tracheal Neoplasms | 1 | 2021 | 124 | 0.170 |
Why?
|
| Fatty Liver | 2 | 2018 | 809 | 0.170 |
Why?
|
| Nitriles | 4 | 2009 | 980 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 4 | 2014 | 625 | 0.170 |
Why?
|
| Quality of Life | 15 | 2022 | 13490 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2021 | 248 | 0.170 |
Why?
|
| Aspirin | 3 | 2017 | 3135 | 0.170 |
Why?
|
| Spironolactone | 1 | 2023 | 415 | 0.170 |
Why?
|
| Cannabidiol | 1 | 2022 | 123 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2021 | 208 | 0.170 |
Why?
|
| Tunica Intima | 3 | 2013 | 459 | 0.170 |
Why?
|
| Procollagen | 5 | 2016 | 189 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2020 | 10760 | 0.170 |
Why?
|
| Automobile Driving | 2 | 2009 | 442 | 0.170 |
Why?
|
| Hematoma, Subdural | 1 | 2020 | 128 | 0.160 |
Why?
|
| Smoking | 6 | 2015 | 9092 | 0.160 |
Why?
|
| No-Reflow Phenomenon | 2 | 2016 | 16 | 0.160 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2009 | 329 | 0.160 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2015 | 598 | 0.160 |
Why?
|
| Proteomics | 4 | 2024 | 3912 | 0.160 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2020 | 119 | 0.160 |
Why?
|
| Proteome | 2 | 2020 | 1890 | 0.160 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 15948 | 0.160 |
Why?
|
| Kidney Calculi | 2 | 2014 | 458 | 0.160 |
Why?
|
| Puberty | 3 | 2013 | 501 | 0.160 |
Why?
|
| Organizational Policy | 2 | 2017 | 435 | 0.160 |
Why?
|
| Odds Ratio | 13 | 2021 | 9669 | 0.160 |
Why?
|
| Self-Examination | 1 | 1999 | 71 | 0.160 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 14783 | 0.160 |
Why?
|
| Tracheal Stenosis | 1 | 2021 | 228 | 0.160 |
Why?
|
| Case-Control Studies | 20 | 2020 | 22291 | 0.160 |
Why?
|
| Football | 1 | 2024 | 506 | 0.160 |
Why?
|
| Risk-Taking | 3 | 2002 | 1023 | 0.150 |
Why?
|
| Prostatic Neoplasms | 8 | 2012 | 11101 | 0.150 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 126 | 0.150 |
Why?
|
| Menstrual Cycle | 2 | 2020 | 546 | 0.150 |
Why?
|
| Spine | 2 | 2023 | 1140 | 0.150 |
Why?
|
| Hepatitis B | 4 | 2005 | 711 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 3 | 2005 | 178 | 0.150 |
Why?
|
| Food, Fortified | 2 | 2018 | 189 | 0.150 |
Why?
|
| Life Change Events | 2 | 2001 | 960 | 0.150 |
Why?
|
| Estrogens | 2 | 2019 | 1536 | 0.150 |
Why?
|
| Collagen Type I | 6 | 2016 | 618 | 0.150 |
Why?
|
| Adipose Tissue, Brown | 2 | 2016 | 776 | 0.150 |
Why?
|
| Graft Rejection | 3 | 2023 | 4492 | 0.150 |
Why?
|
| Antithrombins | 1 | 2021 | 294 | 0.150 |
Why?
|
| Cross-Sectional Studies | 21 | 2024 | 26379 | 0.150 |
Why?
|
| Luteinizing Hormone | 3 | 2010 | 822 | 0.150 |
Why?
|
| Aortic Valve | 2 | 2020 | 1970 | 0.150 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 266 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1351 | 0.150 |
Why?
|
| Menstruation | 2 | 2017 | 310 | 0.150 |
Why?
|
| Hemodynamics | 4 | 2022 | 4194 | 0.150 |
Why?
|
| Carboplatin | 7 | 2022 | 797 | 0.150 |
Why?
|
| Androgens | 4 | 2019 | 1281 | 0.140 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2018 | 72 | 0.140 |
Why?
|
| Models, Genetic | 4 | 1997 | 3447 | 0.140 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 219 | 0.140 |
Why?
|
| Dyslipidemias | 2 | 2020 | 873 | 0.140 |
Why?
|
| Thrombectomy | 3 | 2017 | 676 | 0.140 |
Why?
|
| Disease-Free Survival | 11 | 2018 | 6847 | 0.140 |
Why?
|
| Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
| Vancomycin | 2 | 2018 | 506 | 0.140 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2020 | 420 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 5 | 2018 | 7477 | 0.140 |
Why?
|
| Methicillin | 1 | 2017 | 62 | 0.140 |
Why?
|
| Phenotype | 8 | 2024 | 16726 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 6082 | 0.140 |
Why?
|
| Adipokines | 2 | 2010 | 309 | 0.140 |
Why?
|
| Microscopy | 1 | 2022 | 909 | 0.140 |
Why?
|
| Probiotics | 1 | 2021 | 387 | 0.140 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 289 | 0.140 |
Why?
|
| Seasons | 3 | 2020 | 1524 | 0.140 |
Why?
|
| Risk Assessment | 22 | 2024 | 24315 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2021 | 430 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2022 | 596 | 0.130 |
Why?
|
| Bone Development | 2 | 2013 | 473 | 0.130 |
Why?
|
| Financing, Personal | 1 | 2019 | 310 | 0.130 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2024 | 887 | 0.130 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 807 | 0.130 |
Why?
|
| Veins | 1 | 2021 | 769 | 0.130 |
Why?
|
| Disability Evaluation | 3 | 2020 | 1835 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 306 | 0.130 |
Why?
|
| Quinolines | 2 | 2018 | 772 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2020 | 588 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 255 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
| Neoplasms | 7 | 2024 | 22371 | 0.130 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.130 |
Why?
|
| Phosphates | 3 | 2009 | 765 | 0.130 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2016 | 48 | 0.130 |
Why?
|
| Pituitary Gland | 2 | 2010 | 634 | 0.130 |
Why?
|
| Angioscopy | 1 | 2015 | 47 | 0.130 |
Why?
|
| Menopause | 2 | 2024 | 1656 | 0.130 |
Why?
|
| Sex Factors | 12 | 2024 | 10632 | 0.130 |
Why?
|
| Polyglactin 910 | 1 | 2016 | 56 | 0.130 |
Why?
|
| Housing | 1 | 2001 | 683 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2005 | 90 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2019 | 939 | 0.130 |
Why?
|
| Folic Acid | 2 | 2018 | 1337 | 0.130 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2018 | 263 | 0.130 |
Why?
|
| Atrial Appendage | 1 | 2019 | 285 | 0.130 |
Why?
|
| Fear | 1 | 2024 | 1495 | 0.130 |
Why?
|
| Liver | 4 | 2019 | 7577 | 0.130 |
Why?
|
| Fibromyalgia | 1 | 2020 | 407 | 0.130 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2013 | 1724 | 0.130 |
Why?
|
| Neurologic Examination | 1 | 1999 | 914 | 0.130 |
Why?
|
| Troponin T | 2 | 2011 | 787 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 5 | 2009 | 714 | 0.120 |
Why?
|
| United States | 28 | 2024 | 73039 | 0.120 |
Why?
|
| Reproduction | 1 | 2020 | 646 | 0.120 |
Why?
|
| Cataract Extraction | 1 | 2019 | 464 | 0.120 |
Why?
|
| Homocysteine | 3 | 2022 | 637 | 0.120 |
Why?
|
| Body Mass Index | 12 | 2024 | 13053 | 0.120 |
Why?
|
| Multivariate Analysis | 14 | 2016 | 12077 | 0.120 |
Why?
|
| Hepatitis B Antibodies | 3 | 2005 | 156 | 0.120 |
Why?
|
| Thrombosis | 3 | 2020 | 2957 | 0.120 |
Why?
|
| Cortical Spreading Depression | 1 | 2019 | 288 | 0.120 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 354 | 0.120 |
Why?
|
| Graft Survival | 3 | 2023 | 3887 | 0.120 |
Why?
|
| Keratinocytes | 1 | 2019 | 876 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2020 | 1191 | 0.120 |
Why?
|
| Lumbar Vertebrae | 4 | 2024 | 1885 | 0.120 |
Why?
|
| Verbal Learning | 1 | 2017 | 465 | 0.120 |
Why?
|
| Quinazolines | 4 | 2022 | 1373 | 0.120 |
Why?
|
| Tonometry, Ocular | 3 | 2024 | 238 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 1805 | 0.120 |
Why?
|
| Phthalazines | 2 | 2014 | 397 | 0.120 |
Why?
|
| Lymphocyte Subsets | 2 | 1993 | 313 | 0.120 |
Why?
|
| Serum | 1 | 2016 | 206 | 0.120 |
Why?
|
| Paclitaxel | 8 | 2022 | 1733 | 0.120 |
Why?
|
| Multiple Sclerosis | 3 | 2013 | 3250 | 0.120 |
Why?
|
| Penicillins | 1 | 2018 | 406 | 0.120 |
Why?
|
| Administration, Cutaneous | 5 | 2020 | 716 | 0.120 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2014 | 14 | 0.120 |
Why?
|
| Combined Modality Therapy | 11 | 2021 | 8542 | 0.120 |
Why?
|
| Disease Progression | 7 | 2024 | 13671 | 0.120 |
Why?
|
| Cohort Studies | 17 | 2024 | 41754 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2012 | 1656 | 0.120 |
Why?
|
| Single-Blind Method | 5 | 2017 | 1587 | 0.110 |
Why?
|
| Endometrial Neoplasms | 4 | 2013 | 1382 | 0.110 |
Why?
|
| Ankle Injuries | 1 | 2018 | 339 | 0.110 |
Why?
|
| Administration, Oral | 7 | 2019 | 4030 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 8054 | 0.110 |
Why?
|
| Stress, Mechanical | 4 | 2022 | 1676 | 0.110 |
Why?
|
| Cerebral Cortex | 3 | 2019 | 5812 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2018 | 346 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 565 | 0.110 |
Why?
|
| Monocytes | 1 | 2023 | 2605 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2015 | 394 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2024 | 3445 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2020 | 2763 | 0.110 |
Why?
|
| Nephrocalcinosis | 1 | 2014 | 51 | 0.110 |
Why?
|
| Hydrodynamics | 3 | 2021 | 167 | 0.110 |
Why?
|
| Androgen Antagonists | 3 | 2008 | 1412 | 0.110 |
Why?
|
| Antipsychotic Agents | 4 | 2019 | 3081 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2023 | 4568 | 0.110 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2019 | 748 | 0.110 |
Why?
|
| Triazoles | 2 | 2009 | 904 | 0.110 |
Why?
|
| Psoriasis | 2 | 2012 | 926 | 0.110 |
Why?
|
| Acupuncture Therapy | 2 | 2009 | 486 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 951 | 0.110 |
Why?
|
| Triage | 2 | 2012 | 997 | 0.110 |
Why?
|
| Pilot Projects | 8 | 2024 | 8741 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1145 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2017 | 3390 | 0.110 |
Why?
|
| Age Factors | 15 | 2020 | 18412 | 0.110 |
Why?
|
| Sialoglycoproteins | 2 | 2004 | 315 | 0.110 |
Why?
|
| Anilides | 2 | 2008 | 413 | 0.110 |
Why?
|
| Patient Transfer | 2 | 2017 | 792 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2023 | 5446 | 0.100 |
Why?
|
| Travel | 1 | 2019 | 805 | 0.100 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2012 | 25 | 0.100 |
Why?
|
| Sentinel Surveillance | 1 | 2015 | 292 | 0.100 |
Why?
|
| Body Weight | 4 | 2018 | 4627 | 0.100 |
Why?
|
| Weight Loss | 1 | 2024 | 2721 | 0.100 |
Why?
|
| Executive Function | 2 | 2022 | 1401 | 0.100 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 1359 | 0.100 |
Why?
|
| Adenosine | 1 | 2017 | 820 | 0.100 |
Why?
|
| Fractures, Stress | 1 | 2015 | 205 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 644 | 0.100 |
Why?
|
| Visual Cortex | 1 | 2020 | 1094 | 0.100 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 537 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2024 | 2655 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 640 | 0.100 |
Why?
|
| Feedback, Physiological | 3 | 2010 | 482 | 0.100 |
Why?
|
| Patient Participation | 2 | 2019 | 1447 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2013 | 76 | 0.100 |
Why?
|
| Blood Coagulation Disorders | 2 | 1993 | 350 | 0.100 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 2202 | 0.100 |
Why?
|
| Mental Recall | 2 | 2017 | 1226 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1995 | 2204 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2002 | 2118 | 0.100 |
Why?
|
| Angina, Unstable | 1 | 2016 | 893 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2018 | 1194 | 0.100 |
Why?
|
| Algorithms | 7 | 2020 | 14164 | 0.100 |
Why?
|
| Uterine Neoplasms | 3 | 2008 | 1424 | 0.100 |
Why?
|
| Heart Injuries | 1 | 2014 | 207 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2019 | 1107 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 6526 | 0.100 |
Why?
|
| Incidence | 12 | 2020 | 21538 | 0.100 |
Why?
|
| Education | 1 | 2015 | 533 | 0.100 |
Why?
|
| Finite Element Analysis | 4 | 2015 | 441 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 1601 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 275 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 36743 | 0.100 |
Why?
|
| Hypertension | 3 | 2022 | 8616 | 0.100 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 15662 | 0.100 |
Why?
|
| Vancomycin Resistance | 1 | 2012 | 125 | 0.100 |
Why?
|
| Arthroscopy | 1 | 2018 | 971 | 0.100 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 4206 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2011 | 35 | 0.100 |
Why?
|
| Gonadotropins | 2 | 2010 | 241 | 0.090 |
Why?
|
| Hip | 1 | 2013 | 256 | 0.090 |
Why?
|
| Hospital Administration | 1 | 2015 | 351 | 0.090 |
Why?
|
| Metabolome | 1 | 2018 | 1009 | 0.090 |
Why?
|
| Arginine Vasopressin | 1 | 2011 | 125 | 0.090 |
Why?
|
| Logistic Models | 9 | 2020 | 13290 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1323 | 0.090 |
Why?
|
| Joint Instability | 1 | 2018 | 803 | 0.090 |
Why?
|
| Thermogenesis | 1 | 2015 | 494 | 0.090 |
Why?
|
| Alcoholism | 1 | 2002 | 1980 | 0.090 |
Why?
|
| HIV | 3 | 2023 | 1597 | 0.090 |
Why?
|
| Cardiovascular System | 1 | 2018 | 841 | 0.090 |
Why?
|
| Inhibins | 2 | 2009 | 210 | 0.090 |
Why?
|
| Warfarin | 1 | 2019 | 1493 | 0.090 |
Why?
|
| Adenoma | 2 | 2011 | 2159 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 2914 | 0.090 |
Why?
|
| CA-125 Antigen | 4 | 2009 | 281 | 0.090 |
Why?
|
| Genetics, Population | 1 | 1996 | 944 | 0.090 |
Why?
|
| Sensitivity and Specificity | 11 | 2015 | 14729 | 0.090 |
Why?
|
| HIV-1 | 9 | 2008 | 6961 | 0.090 |
Why?
|
| Colitis | 1 | 2019 | 1242 | 0.090 |
Why?
|
| Plasma Cells | 1 | 2014 | 599 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 3914 | 0.090 |
Why?
|
| Survival Rate | 6 | 2021 | 12840 | 0.090 |
Why?
|
| Fibronectins | 1 | 2014 | 722 | 0.090 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 416 | 0.090 |
Why?
|
| Primates | 2 | 2023 | 520 | 0.090 |
Why?
|
| Boston | 9 | 2016 | 9374 | 0.090 |
Why?
|
| Observer Variation | 5 | 2017 | 2622 | 0.090 |
Why?
|
| Tosyl Compounds | 2 | 2008 | 115 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1751 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2014 | 542 | 0.090 |
Why?
|
| Neuromuscular Diseases | 1 | 2013 | 260 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 662 | 0.090 |
Why?
|
| Seminiferous Tubules | 1 | 2009 | 25 | 0.090 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 58 | 0.090 |
Why?
|
| Social Behavior | 3 | 2009 | 1147 | 0.090 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 91 | 0.090 |
Why?
|
| Attitude | 1 | 2015 | 771 | 0.090 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 455 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2021 | 2479 | 0.090 |
Why?
|
| Sports | 1 | 2016 | 703 | 0.090 |
Why?
|
| Electrocardiography | 4 | 2019 | 6412 | 0.080 |
Why?
|
| Survivors | 3 | 2010 | 2381 | 0.080 |
Why?
|
| Pyrazines | 1 | 2015 | 1205 | 0.080 |
Why?
|
| Child | 21 | 2023 | 80917 | 0.080 |
Why?
|
| Hepatitis B virus | 2 | 2003 | 533 | 0.080 |
Why?
|
| Glycopeptides | 1 | 2011 | 225 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 969 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 2931 | 0.080 |
Why?
|
| Peptides | 6 | 2016 | 4354 | 0.080 |
Why?
|
| Adolescent Development | 1 | 2013 | 276 | 0.080 |
Why?
|
| Attitude to Health | 1 | 1998 | 2025 | 0.080 |
Why?
|
| Substance-Related Disorders | 3 | 2023 | 4423 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2011 | 326 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 829 | 0.080 |
Why?
|
| Metabolomics | 2 | 2018 | 1674 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2015 | 741 | 0.080 |
Why?
|
| Japan | 4 | 2020 | 1418 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 2076 | 0.080 |
Why?
|
| Enterobacteriaceae | 1 | 2010 | 161 | 0.080 |
Why?
|
| Obesity, Abdominal | 1 | 2012 | 375 | 0.080 |
Why?
|
| Endoscopy | 1 | 2019 | 1854 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2015 | 1599 | 0.080 |
Why?
|
| Heart | 2 | 2024 | 4446 | 0.080 |
Why?
|
| beta-Lactams | 1 | 2010 | 158 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2013 | 640 | 0.080 |
Why?
|
| Radioimmunoassay | 3 | 2010 | 863 | 0.080 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 2230 | 0.080 |
Why?
|
| Fibrinogen | 2 | 2022 | 891 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 923 | 0.080 |
Why?
|
| Prosthesis Failure | 2 | 2014 | 1208 | 0.080 |
Why?
|
| Urinary Calculi | 1 | 2009 | 81 | 0.080 |
Why?
|
| Diagnosis, Differential | 8 | 2018 | 13014 | 0.080 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 1668 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 9263 | 0.080 |
Why?
|
| Neuropsychological Tests | 4 | 2022 | 7140 | 0.080 |
Why?
|
| Donor Selection | 1 | 2011 | 240 | 0.080 |
Why?
|
| Cardiac Volume | 1 | 2009 | 197 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1160 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 804 | 0.080 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2010 | 190 | 0.080 |
Why?
|
| Cytokines | 1 | 2023 | 7453 | 0.080 |
Why?
|
| Hyperplasia | 4 | 2013 | 1151 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2014 | 707 | 0.080 |
Why?
|
| Seminiferous Epithelium | 1 | 2008 | 9 | 0.080 |
Why?
|
| Osteocalcin | 2 | 2006 | 275 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1546 | 0.080 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 5176 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2009 | 2741 | 0.080 |
Why?
|
| Sick Role | 2 | 1999 | 229 | 0.080 |
Why?
|
| Genetic Linkage | 3 | 1998 | 2342 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 587 | 0.070 |
Why?
|
| HLA Antigens | 2 | 2011 | 1334 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 620 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2009 | 361 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2013 | 752 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 2596 | 0.070 |
Why?
|
| Cushing Syndrome | 1 | 2009 | 241 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2018 | 2596 | 0.070 |
Why?
|
| Carcinoma, Papillary | 2 | 2011 | 793 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 2565 | 0.070 |
Why?
|
| Terminal Care | 1 | 2020 | 1770 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2015 | 1030 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2012 | 612 | 0.070 |
Why?
|
| ROC Curve | 5 | 2016 | 3628 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 2032 | 0.070 |
Why?
|
| Microspheres | 1 | 2011 | 788 | 0.070 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 338 | 0.070 |
Why?
|
| HIV Seropositivity | 5 | 2005 | 966 | 0.070 |
Why?
|
| Regression Analysis | 6 | 2013 | 6340 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2009 | 218 | 0.070 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2008 | 138 | 0.070 |
Why?
|
| Osteopathic Medicine | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2009 | 480 | 0.070 |
Why?
|
| Anabolic Agents | 1 | 2010 | 256 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2448 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2021 | 4852 | 0.070 |
Why?
|
| Injections, Subcutaneous | 3 | 2020 | 687 | 0.070 |
Why?
|
| Area Under Curve | 4 | 2016 | 1643 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2020 | 3007 | 0.070 |
Why?
|
| Prosthesis Design | 4 | 2016 | 2125 | 0.070 |
Why?
|
| C-Reactive Protein | 4 | 2023 | 3858 | 0.070 |
Why?
|
| Pelvic Infection | 1 | 2006 | 12 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2011 | 1134 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 849 | 0.070 |
Why?
|
| Hirudins | 2 | 2021 | 179 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2019 | 912 | 0.070 |
Why?
|
| Aneurysm | 1 | 2010 | 343 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2011 | 592 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2014 | 1288 | 0.070 |
Why?
|
| Isoantibodies | 1 | 2011 | 681 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2020 | 4755 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 12252 | 0.070 |
Why?
|
| Piperazines | 2 | 2014 | 2554 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2012 | 881 | 0.070 |
Why?
|
| Linear Models | 5 | 2017 | 5884 | 0.070 |
Why?
|
| Phosphorus | 1 | 2008 | 336 | 0.070 |
Why?
|
| California | 5 | 2017 | 1438 | 0.070 |
Why?
|
| Cardiomegaly | 1 | 2009 | 591 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 1309 | 0.070 |
Why?
|
| Health | 1 | 2009 | 398 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2014 | 1093 | 0.070 |
Why?
|
| Emergency Service, Hospital | 4 | 2015 | 7951 | 0.070 |
Why?
|
| Leukopenia | 1 | 2007 | 212 | 0.070 |
Why?
|
| Schizophrenia | 6 | 2002 | 6983 | 0.070 |
Why?
|
| Reference Values | 4 | 2018 | 4938 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 892 | 0.060 |
Why?
|
| Anti-HIV Agents | 3 | 2020 | 4573 | 0.060 |
Why?
|
| Comorbidity | 7 | 2020 | 10590 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2020 | 5622 | 0.060 |
Why?
|
| Bacteremia | 1 | 2013 | 986 | 0.060 |
Why?
|
| Pertussis Vaccine | 1 | 2005 | 39 | 0.060 |
Why?
|
| Bordetella pertussis | 1 | 2005 | 45 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 2538 | 0.060 |
Why?
|
| Postprandial Period | 1 | 2008 | 320 | 0.060 |
Why?
|
| Fluorouracil | 2 | 2023 | 1652 | 0.060 |
Why?
|
| Femur Neck | 2 | 2024 | 318 | 0.060 |
Why?
|
| Gene Frequency | 1 | 1993 | 3623 | 0.060 |
Why?
|
| Wound Healing | 2 | 2015 | 2809 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2024 | 5315 | 0.060 |
Why?
|
| Multiple Birth Offspring | 1 | 2005 | 22 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 2496 | 0.060 |
Why?
|
| Adaptation, Psychological | 3 | 2010 | 2663 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 458 | 0.060 |
Why?
|
| China | 3 | 2017 | 2395 | 0.060 |
Why?
|
| Thyroxine | 2 | 2023 | 665 | 0.060 |
Why?
|
| Receptors, Estrogen | 2 | 2013 | 2253 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3573 | 0.060 |
Why?
|
| Crohn Disease | 2 | 2009 | 2295 | 0.060 |
Why?
|
| Abdominal Abscess | 1 | 2006 | 153 | 0.060 |
Why?
|
| Whooping Cough | 1 | 2005 | 87 | 0.060 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 1263 | 0.060 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 956 | 0.060 |
Why?
|
| Thyroid Gland | 1 | 2011 | 1171 | 0.060 |
Why?
|
| Acromegaly | 1 | 2008 | 317 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2011 | 1505 | 0.060 |
Why?
|
| Adiponectin | 4 | 2015 | 1117 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3252 | 0.060 |
Why?
|
| Patient Admission | 1 | 2012 | 1365 | 0.060 |
Why?
|
| Thrombolytic Therapy | 1 | 2013 | 2055 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5717 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 2337 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2012 | 7876 | 0.060 |
Why?
|
| Acute Lung Injury | 1 | 2008 | 377 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 2022 | 3228 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 12800 | 0.060 |
Why?
|
| Confidence Intervals | 4 | 2014 | 2923 | 0.060 |
Why?
|
| Models, Statistical | 2 | 1997 | 5107 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 998 | 0.060 |
Why?
|
| Hospitalization | 1 | 2024 | 10840 | 0.060 |
Why?
|
| Thyroid Nodule | 1 | 2011 | 767 | 0.060 |
Why?
|
| Dialysis | 1 | 2004 | 72 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2014 | 6283 | 0.060 |
Why?
|
| Metformin | 1 | 2012 | 909 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4362 | 0.060 |
Why?
|
| Neutropenia | 1 | 2009 | 892 | 0.060 |
Why?
|
| Postoperative Complications | 4 | 2024 | 15832 | 0.060 |
Why?
|
| Animals | 13 | 2023 | 169246 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 131 | 0.060 |
Why?
|
| Homocystine | 1 | 2003 | 21 | 0.050 |
Why?
|
| Siblings | 1 | 2008 | 828 | 0.050 |
Why?
|
| Pedigree | 5 | 2007 | 4539 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2009 | 969 | 0.050 |
Why?
|
| Glucose Tolerance Test | 3 | 2015 | 1183 | 0.050 |
Why?
|
| Drug Substitution | 2 | 2017 | 291 | 0.050 |
Why?
|
| Dinoprost | 1 | 2023 | 139 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2056 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 1998 | 4310 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1406 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 945 | 0.050 |
Why?
|
| Food Industry | 1 | 2003 | 68 | 0.050 |
Why?
|
| Mathematics | 2 | 1996 | 704 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2017 | 2298 | 0.050 |
Why?
|
| Emotions | 1 | 2015 | 2767 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 119 | 0.050 |
Why?
|
| Neisseria meningitidis | 1 | 2003 | 111 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2008 | 644 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 8647 | 0.050 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 2216 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 751 | 0.050 |
Why?
|
| Pregnancy | 6 | 2024 | 30256 | 0.050 |
Why?
|
| Agonistic Behavior | 1 | 2002 | 14 | 0.050 |
Why?
|
| Receptor, erbB-2 | 2 | 2013 | 2603 | 0.050 |
Why?
|
| Viral Load | 3 | 2020 | 3396 | 0.050 |
Why?
|
| Androstenedione | 1 | 2002 | 132 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2006 | 887 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 2011 | 1322 | 0.050 |
Why?
|
| Risk | 4 | 2019 | 9613 | 0.050 |
Why?
|
| Age Determination by Skeleton | 2 | 2013 | 126 | 0.050 |
Why?
|
| Meningococcal Vaccines | 1 | 2003 | 96 | 0.050 |
Why?
|
| Patient Selection | 4 | 2020 | 4260 | 0.050 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2024 | 167 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2011 | 1216 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 2916 | 0.050 |
Why?
|
| Blood Transfusion | 2 | 2008 | 1309 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2003 | 248 | 0.050 |
Why?
|
| Hypothalamus | 1 | 2007 | 1004 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2015 | 591 | 0.050 |
Why?
|
| Social Environment | 2 | 2002 | 1012 | 0.050 |
Why?
|
| Pancreatic Diseases | 1 | 2024 | 354 | 0.050 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 165 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 141 | 0.050 |
Why?
|
| Calcium | 4 | 2009 | 5792 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 874 | 0.050 |
Why?
|
| Prothrombin | 1 | 2022 | 194 | 0.050 |
Why?
|
| Chimerism | 1 | 2023 | 156 | 0.050 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 12543 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2011 | 2629 | 0.050 |
Why?
|
| Ischemia | 1 | 2011 | 1900 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 5520 | 0.050 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2001 | 24 | 0.050 |
Why?
|
| Leucine | 1 | 2023 | 547 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2009 | 1965 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2002 | 116 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2003 | 237 | 0.050 |
Why?
|
| Macrophages | 3 | 2022 | 5799 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 2257 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2008 | 1157 | 0.050 |
Why?
|
| Cholesterol, HDL | 2 | 2022 | 1820 | 0.050 |
Why?
|
| Age Distribution | 3 | 2015 | 2873 | 0.050 |
Why?
|
| Lactobacillus plantarum | 1 | 2021 | 6 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 643 | 0.050 |
Why?
|
| Mass Screening | 2 | 2013 | 5458 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2020 | 1609 | 0.050 |
Why?
|
| Prone Position | 1 | 2022 | 203 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 389 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2003 | 334 | 0.050 |
Why?
|
| Cisplatin | 2 | 2020 | 1660 | 0.050 |
Why?
|
| Tunica Media | 2 | 2015 | 111 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 6514 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3814 | 0.050 |
Why?
|
| Vitamin D | 3 | 2013 | 3311 | 0.050 |
Why?
|
| Random Allocation | 2 | 2017 | 2396 | 0.050 |
Why?
|
| Rotavirus Vaccines | 1 | 2002 | 62 | 0.050 |
Why?
|
| Insulin | 4 | 2023 | 6607 | 0.050 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2001 | 39 | 0.050 |
Why?
|
| Stroke | 2 | 2019 | 9755 | 0.050 |
Why?
|
| Mind-Body Therapies | 1 | 2024 | 294 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2023 | 528 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 2002 | 85 | 0.050 |
Why?
|
| Radiography | 4 | 2015 | 6983 | 0.050 |
Why?
|
| Photography | 1 | 2024 | 537 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2019 | 613 | 0.050 |
Why?
|
| Intussusception | 1 | 2002 | 116 | 0.050 |
Why?
|
| Rotarod Performance Test | 1 | 2020 | 63 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2006 | 863 | 0.050 |
Why?
|
| Probability | 2 | 1997 | 2479 | 0.050 |
Why?
|
| Drainage | 1 | 2006 | 1183 | 0.040 |
Why?
|
| Deltaretrovirus Infections | 2 | 1991 | 25 | 0.040 |
Why?
|
| Microcirculation | 2 | 2016 | 1281 | 0.040 |
Why?
|
| Losartan | 1 | 2022 | 262 | 0.040 |
Why?
|
| Weight Gain | 2 | 2023 | 2359 | 0.040 |
Why?
|
| Viremia | 1 | 2003 | 726 | 0.040 |
Why?
|
| Pipecolic Acids | 1 | 2021 | 77 | 0.040 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2005 | 504 | 0.040 |
Why?
|
| Curettage | 1 | 2020 | 74 | 0.040 |
Why?
|
| Topotecan | 3 | 2006 | 131 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 9015 | 0.040 |
Why?
|
| Haloperidol | 1 | 2002 | 394 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2003 | 404 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2024 | 2204 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2020 | 135 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2001 | 279 | 0.040 |
Why?
|
| Penile Erection | 1 | 2020 | 100 | 0.040 |
Why?
|
| Proteins | 2 | 2014 | 6009 | 0.040 |
Why?
|
| Carcinoma | 1 | 2011 | 2332 | 0.040 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 7852 | 0.040 |
Why?
|
| Life Style | 1 | 2012 | 3932 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 398 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 204 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2003 | 420 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 6974 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 1456 | 0.040 |
Why?
|
| Data Collection | 3 | 2012 | 3327 | 0.040 |
Why?
|
| Prednisone | 1 | 2004 | 1567 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 1903 | 0.040 |
Why?
|
| Abdominal Fat | 2 | 2014 | 220 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 426 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1437 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 899 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 1993 | 994 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2015 | 3857 | 0.040 |
Why?
|
| Recurrence | 4 | 2017 | 8509 | 0.040 |
Why?
|
| Neurons | 1 | 2019 | 9514 | 0.040 |
Why?
|
| Kidney | 3 | 2023 | 7064 | 0.040 |
Why?
|
| Acute Disease | 4 | 2012 | 7243 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2024 | 417 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2016 | 10101 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2007 | 2003 | 0.040 |
Why?
|
| Cognition Disorders | 2 | 2007 | 3980 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2003 | 414 | 0.040 |
Why?
|
| Electroencephalography | 3 | 2022 | 6314 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 622 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2022 | 2909 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2004 | 752 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1304 | 0.040 |
Why?
|
| Regional Blood Flow | 2 | 2014 | 1500 | 0.040 |
Why?
|
| Glucose | 2 | 2023 | 4352 | 0.040 |
Why?
|
| Gels | 1 | 2020 | 423 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3109 | 0.040 |
Why?
|
| Drug Interactions | 3 | 2010 | 1419 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2019 | 152 | 0.040 |
Why?
|
| Desogestrel | 1 | 2018 | 18 | 0.040 |
Why?
|
| Arthritis | 1 | 2024 | 684 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 340 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 246 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 163 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 2661 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1791 | 0.040 |
Why?
|
| Sepsis | 1 | 2013 | 2608 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 396 | 0.040 |
Why?
|
| Perfusion | 1 | 2023 | 1401 | 0.040 |
Why?
|
| Transdermal Patch | 1 | 2018 | 51 | 0.040 |
Why?
|
| Maze Learning | 1 | 2020 | 482 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 21206 | 0.040 |
Why?
|
| Edema | 1 | 2022 | 765 | 0.040 |
Why?
|
| Colorado | 1 | 1998 | 167 | 0.040 |
Why?
|
| Ciliary Body | 1 | 2019 | 168 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 2003 | 529 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2007 | 1085 | 0.040 |
Why?
|
| Appetite Stimulants | 1 | 2018 | 14 | 0.040 |
Why?
|
| Neurites | 1 | 2020 | 389 | 0.040 |
Why?
|
| Patient Compliance | 4 | 2010 | 2697 | 0.040 |
Why?
|
| Glucose Clamp Technique | 1 | 2018 | 263 | 0.040 |
Why?
|
| Receptors, LHRH | 2 | 2009 | 158 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 2360 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 1049 | 0.040 |
Why?
|
| Ethinyl Estradiol | 1 | 2018 | 114 | 0.040 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 203 | 0.040 |
Why?
|
| Platelet-Rich Plasma | 1 | 2021 | 180 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2024 | 1140 | 0.040 |
Why?
|
| Psychopharmacology | 1 | 2019 | 146 | 0.040 |
Why?
|
| Philadelphia | 1 | 2018 | 271 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 716 | 0.040 |
Why?
|
| Comprehensive Health Care | 1 | 1998 | 123 | 0.040 |
Why?
|
| Doxorubicin | 4 | 2006 | 2234 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 877 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2003 | 764 | 0.040 |
Why?
|
| Schizophrenic Psychology | 2 | 2002 | 1649 | 0.040 |
Why?
|
| Clindamycin | 1 | 2018 | 138 | 0.040 |
Why?
|
| Pancreas | 1 | 2024 | 1700 | 0.040 |
Why?
|
| Health Status | 3 | 2024 | 4091 | 0.040 |
Why?
|
| Mice | 6 | 2022 | 82029 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 262 | 0.040 |
Why?
|
| Collagen | 1 | 2005 | 2643 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 991 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2009 | 259 | 0.040 |
Why?
|
| Internal-External Control | 1 | 1999 | 348 | 0.040 |
Why?
|
| Genotype | 4 | 2019 | 13045 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2019 | 703 | 0.030 |
Why?
|
| Commerce | 1 | 2002 | 612 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2015 | 2937 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 1926 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 2 | 2012 | 1083 | 0.030 |
Why?
|
| Creatinine | 1 | 2022 | 1918 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2019 | 877 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 1789 | 0.030 |
Why?
|
| Genetic Markers | 3 | 2016 | 2603 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2024 | 1200 | 0.030 |
Why?
|
| Leptin | 2 | 2018 | 1599 | 0.030 |
Why?
|
| Clozapine | 1 | 2000 | 509 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1997 | 247 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2018 | 299 | 0.030 |
Why?
|
| Europe | 2 | 2020 | 3436 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2017 | 525 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 17140 | 0.030 |
Why?
|
| Microvessels | 1 | 2020 | 585 | 0.030 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 1999 | 256 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 898 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2016 | 202 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 13676 | 0.030 |
Why?
|
| Reoperation | 2 | 2021 | 4329 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2018 | 301 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 629 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 1988 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 1883 | 0.030 |
Why?
|
| Universal Precautions | 1 | 2015 | 34 | 0.030 |
Why?
|
| Antioxidants | 1 | 2023 | 1673 | 0.030 |
Why?
|
| Iron | 1 | 2024 | 1813 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2018 | 247 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 348 | 0.030 |
Why?
|
| Elastic Tissue | 1 | 2015 | 66 | 0.030 |
Why?
|
| Suction | 1 | 2016 | 268 | 0.030 |
Why?
|
| Drive | 1 | 2015 | 34 | 0.030 |
Why?
|
| Immunoassay | 2 | 2011 | 746 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2018 | 542 | 0.030 |
Why?
|
| Psychometrics | 2 | 2010 | 3063 | 0.030 |
Why?
|
| Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 2016 | 163 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 246 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2024 | 2055 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2020 | 683 | 0.030 |
Why?
|
| Program Evaluation | 2 | 2019 | 2507 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2013 | 2089 | 0.030 |
Why?
|
| Copper | 1 | 2017 | 368 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 364 | 0.030 |
Why?
|
| Cognition | 2 | 2022 | 7073 | 0.030 |
Why?
|
| Methicillin Resistance | 1 | 2015 | 198 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5536 | 0.030 |
Why?
|
| Nuclear Family | 1 | 1996 | 311 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 590 | 0.030 |
Why?
|
| Exercise | 2 | 2013 | 5955 | 0.030 |
Why?
|
| Placenta | 1 | 2024 | 1725 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2015 | 1841 | 0.030 |
Why?
|
| Infant | 6 | 2023 | 36535 | 0.030 |
Why?
|
| Feces | 1 | 2021 | 1511 | 0.030 |
Why?
|
| Adipogenesis | 1 | 2017 | 370 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2009 | 832 | 0.030 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 2913 | 0.030 |
Why?
|
| Membranes, Artificial | 1 | 2016 | 367 | 0.030 |
Why?
|
| Myocardial Ischemia | 2 | 2017 | 2138 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2020 | 3800 | 0.030 |
Why?
|
| Gonads | 1 | 2014 | 109 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 570 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 527 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 960 | 0.030 |
Why?
|
| Specialization | 1 | 1998 | 779 | 0.030 |
Why?
|
| Deltaretrovirus Antibodies | 2 | 1991 | 9 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2014 | 187 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1088 | 0.030 |
Why?
|
| Terminology as Topic | 2 | 2011 | 1542 | 0.030 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 1999 | 558 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2020 | 8080 | 0.030 |
Why?
|
| Social Class | 1 | 2002 | 2008 | 0.030 |
Why?
|
| Anthropometry | 2 | 2010 | 1346 | 0.030 |
Why?
|
| Brain Concussion | 1 | 2024 | 1435 | 0.030 |
Why?
|
| Testis | 2 | 2009 | 783 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2021 | 42669 | 0.030 |
Why?
|
| Chemical Phenomena | 1 | 2013 | 486 | 0.030 |
Why?
|
| Capsules | 1 | 2013 | 193 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 149 | 0.030 |
Why?
|
| Exfoliation Syndrome | 1 | 2014 | 113 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 964 | 0.030 |
Why?
|
| Hospitals | 2 | 2020 | 3886 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 2062 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2020 | 1862 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2023 | 3139 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 1892 | 0.020 |
Why?
|
| Osteopontin | 2 | 2004 | 306 | 0.020 |
Why?
|
| Models, Animal | 1 | 2019 | 2120 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1625 | 0.020 |
Why?
|
| Porosity | 1 | 2013 | 352 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2006 | 631 | 0.020 |
Why?
|
| Focus Groups | 1 | 1998 | 1460 | 0.020 |
Why?
|
| Hemophilia A | 2 | 1995 | 359 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 2907 | 0.020 |
Why?
|
| Rupture | 1 | 2013 | 444 | 0.020 |
Why?
|
| Australia | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 476 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 794 | 0.020 |
Why?
|
| Diarrhea | 2 | 2013 | 1320 | 0.020 |
Why?
|
| Nose | 1 | 2015 | 522 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1996 | 0.020 |
Why?
|
| Diet | 2 | 2007 | 8089 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 2709 | 0.020 |
Why?
|
| Thinness | 1 | 2015 | 483 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2020 | 824 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 506 | 0.020 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2013 | 127 | 0.020 |
Why?
|
| Spleen | 1 | 2017 | 2295 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 11095 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2016 | 845 | 0.020 |
Why?
|
| Underachievement | 1 | 1991 | 15 | 0.020 |
Why?
|
| Bipolar Disorder | 2 | 2000 | 5130 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 7454 | 0.020 |
Why?
|
| Quadriplegia | 1 | 2013 | 227 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2726 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 996 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 702 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1993 | 371 | 0.020 |
Why?
|
| Spinal Dysraphism | 1 | 2013 | 179 | 0.020 |
Why?
|
| Autopsy | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2013 | 534 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 574 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4270 | 0.020 |
Why?
|
| Necrosis | 1 | 2015 | 1616 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 1998 | 794 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 22379 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 917 | 0.020 |
Why?
|
| Length of Stay | 2 | 2016 | 6498 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 3929 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 1991 | 256 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1126 | 0.020 |
Why?
|
| Women's Health | 1 | 2020 | 2082 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 3231 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3556 | 0.020 |
Why?
|
| Income | 1 | 2019 | 1878 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2015 | 2278 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 682 | 0.020 |
Why?
|
| Medicine | 1 | 1998 | 945 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 2012 | 492 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 163 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2744 | 0.020 |
Why?
|
| Contrast Media | 2 | 2014 | 5330 | 0.020 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 1 | 2009 | 29 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2019 | 2258 | 0.020 |
Why?
|
| Adipocytes | 1 | 2017 | 1197 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2020 | 2981 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 1837 | 0.020 |
Why?
|
| Outpatients | 1 | 2018 | 1600 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 342 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1993 | 549 | 0.020 |
Why?
|
| American Heart Association | 1 | 2014 | 1050 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 1566 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2024 | 9384 | 0.020 |
Why?
|
| Pain | 1 | 2024 | 5100 | 0.020 |
Why?
|
| Sexual Partners | 2 | 1991 | 805 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2010 | 183 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 2593 | 0.020 |
Why?
|
| Vaccination | 1 | 2021 | 3437 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2019 | 1951 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4912 | 0.020 |
Why?
|
| Palliative Care | 1 | 2004 | 3643 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 4249 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2018 | 2191 | 0.020 |
Why?
|
| Alleles | 2 | 2007 | 6894 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 2627 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3948 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2023 | 26422 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Speech Recognition Software | 1 | 2009 | 74 | 0.020 |
Why?
|
| New England | 1 | 2012 | 1058 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2021 | 3467 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 1196 | 0.020 |
Why?
|
| Seizures | 1 | 2021 | 2998 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 299 | 0.020 |
Why?
|
| Fathers | 1 | 2011 | 377 | 0.020 |
Why?
|
| Phototherapy | 1 | 2011 | 368 | 0.020 |
Why?
|
| Biopsy | 1 | 2020 | 6793 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 422 | 0.020 |
Why?
|
| Policy | 1 | 2012 | 513 | 0.020 |
Why?
|
| Informed Consent | 1 | 2015 | 1010 | 0.020 |
Why?
|
| Brain | 3 | 2024 | 27360 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 408 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1232 | 0.020 |
Why?
|
| Cerebral Palsy | 1 | 2013 | 480 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 389 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2012 | 791 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 1177 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2007 | 95 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 2185 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2011 | 488 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2009 | 619 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 577 | 0.020 |
Why?
|
| Dermatologic Agents | 1 | 2011 | 313 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2011 | 917 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 643 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 280 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 598 | 0.020 |
Why?
|
| Glutamates | 1 | 2008 | 385 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 1702 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 1417 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 1389 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 2512 | 0.020 |
Why?
|
| Body Constitution | 1 | 2007 | 273 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2008 | 124 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 18065 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2007 | 384 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1998 | 2085 | 0.020 |
Why?
|
| Apolipoprotein E2 | 1 | 2007 | 134 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 592 | 0.020 |
Why?
|
| Puberty, Delayed | 1 | 2007 | 124 | 0.020 |
Why?
|
| Skin | 1 | 2020 | 4503 | 0.020 |
Why?
|
| Kallmann Syndrome | 1 | 2007 | 142 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1470 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 1135 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9561 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 5755 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 2227 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2012 | 1189 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2010 | 591 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2008 | 349 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1557 | 0.020 |
Why?
|
| Health Resources | 1 | 2012 | 950 | 0.020 |
Why?
|
| Hepatitis A Vaccines | 1 | 2005 | 26 | 0.020 |
Why?
|
| Urethra | 1 | 2008 | 406 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2009 | 597 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 622 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 3114 | 0.020 |
Why?
|
| Chromosome Mapping | 3 | 1998 | 4620 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3239 | 0.020 |
Why?
|
| Personality Inventory | 2 | 1999 | 1018 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 9118 | 0.020 |
Why?
|
| Homeostasis | 1 | 2017 | 3348 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 174 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 4413 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2914 | 0.020 |
Why?
|
| Hormones | 1 | 2009 | 866 | 0.020 |
Why?
|
| Antigens, CD | 2 | 1993 | 4035 | 0.020 |
Why?
|
| Public Health | 1 | 1998 | 2679 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 1864 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3603 | 0.020 |
Why?
|
| Exercise Test | 1 | 2013 | 2186 | 0.020 |
Why?
|
| Triglycerides | 1 | 2013 | 2464 | 0.010 |
Why?
|
| Calcitriol | 1 | 2006 | 303 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 551 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2592 | 0.010 |
Why?
|
| Behavior Control | 1 | 2004 | 46 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2907 | 0.010 |
Why?
|
| Research Design | 1 | 2020 | 6211 | 0.010 |
Why?
|
| Organ Size | 1 | 2009 | 2267 | 0.010 |
Why?
|
| Steroids | 1 | 2009 | 938 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 293 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2012 | 1786 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 6229 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 2227 | 0.010 |
Why?
|
| Immunization | 1 | 2008 | 1219 | 0.010 |
Why?
|
| Poverty | 1 | 2016 | 2720 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 1967 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2008 | 942 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 2107 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 2008 | 487 | 0.010 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 56 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2521 | 0.010 |
Why?
|
| World Health Organization | 1 | 2010 | 1329 | 0.010 |
Why?
|
| Pelvis | 1 | 2008 | 736 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2014 | 5902 | 0.010 |
Why?
|
| Myocardium | 1 | 2016 | 4788 | 0.010 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 62 | 0.010 |
Why?
|
| Rectum | 1 | 2008 | 900 | 0.010 |
Why?
|
| Pyridoxal Phosphate | 1 | 2003 | 123 | 0.010 |
Why?
|
| Psychology | 1 | 2005 | 353 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2006 | 23645 | 0.010 |
Why?
|
| Heart Atria | 1 | 2009 | 1361 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 1063 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 5341 | 0.010 |
Why?
|
| Family Characteristics | 1 | 2008 | 1003 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2015 | 3205 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2007 | 1219 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 712 | 0.010 |
Why?
|
| Serotyping | 1 | 2003 | 331 | 0.010 |
Why?
|
| Control Groups | 1 | 2002 | 107 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2003 | 294 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 1328 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2008 | 8543 | 0.010 |
Why?
|
| Urban Population | 1 | 2010 | 2046 | 0.010 |
Why?
|
| Government Programs | 1 | 2004 | 278 | 0.010 |
Why?
|
| Vagina | 1 | 2008 | 850 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 10399 | 0.010 |
Why?
|
| Asthma | 1 | 2001 | 6291 | 0.010 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 276 | 0.010 |
Why?
|
| Primary Health Care | 1 | 1998 | 4746 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 3272 | 0.010 |
Why?
|
| Decision Making | 1 | 2015 | 3953 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2001 | 16045 | 0.010 |
Why?
|
| Sperm Count | 1 | 2002 | 228 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 2002 | 153 | 0.010 |
Why?
|
| Software | 1 | 1996 | 4478 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 2001 | 70 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 3269 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 640 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2009 | 1188 | 0.010 |
Why?
|
| Affect | 1 | 2009 | 1495 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 553 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3782 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3533 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18349 | 0.010 |
Why?
|
| Sodium | 1 | 2006 | 1597 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1015 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 1989 | 0.010 |
Why?
|
| Mothers | 1 | 2011 | 2209 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2271 | 0.010 |
Why?
|
| Age of Onset | 1 | 2008 | 3347 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1996 | 6611 | 0.010 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2000 | 108 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 2430 | 0.010 |
Why?
|
| Family | 1 | 1991 | 3209 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 863 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 2798 | 0.010 |
Why?
|
| Antibodies | 1 | 2008 | 2421 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 2003 | 529 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 1247 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2003 | 677 | 0.010 |
Why?
|
| Motivation | 1 | 2010 | 2020 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 2784 | 0.010 |
Why?
|
| Energy Intake | 1 | 2007 | 2146 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 1505 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2009 | 2197 | 0.010 |
Why?
|
| Assertiveness | 1 | 1999 | 18 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2002 | 638 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2012 | 3239 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2002 | 657 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 2001 | 373 | 0.010 |
Why?
|
| Florida | 2 | 1991 | 417 | 0.010 |
Why?
|
| Leukocytes | 1 | 2007 | 2035 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1159 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 2463 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 677 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 411 | 0.010 |
Why?
|
| Critical Illness | 1 | 2011 | 2756 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 1999 | 2783 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9495 | 0.010 |
Why?
|
| Occipital Lobe | 1 | 1999 | 376 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 4146 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 378 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2009 | 2187 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 3428 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1998 | 350 | 0.010 |
Why?
|
| Canada | 1 | 2002 | 2130 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1998 | 370 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1998 | 361 | 0.010 |
Why?
|
| Limbic System | 1 | 1999 | 424 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 452 | 0.010 |
Why?
|
| Echocardiography | 1 | 2009 | 5047 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 2000 | 409 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1998 | 534 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 781 | 0.010 |
Why?
|
| Lod Score | 1 | 1997 | 600 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2002 | 1138 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3800 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2011 | 3803 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8317 | 0.010 |
Why?
|
| Epilepsy | 1 | 1991 | 3327 | 0.010 |
Why?
|
| Genome, Human | 2 | 1998 | 4446 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2002 | 2363 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2008 | 6004 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1995 | 141 | 0.010 |
Why?
|
| Confidentiality | 1 | 1998 | 607 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1999 | 866 | 0.010 |
Why?
|
| Atrophy | 1 | 1999 | 1646 | 0.010 |
Why?
|
| Mutation | 2 | 2009 | 30238 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 3721 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2005 | 3073 | 0.010 |
Why?
|
| Demography | 1 | 1997 | 1641 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 3703 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 1998 | 1426 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1998 | 2264 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 1 | 1991 | 16 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 2862 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2599 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 9523 | 0.010 |
Why?
|
| Psychosocial Deprivation | 1 | 1991 | 101 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 5367 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1998 | 1892 | 0.010 |
Why?
|
| West Indies | 1 | 1989 | 32 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2000 | 6029 | 0.010 |
Why?
|
| San Francisco | 1 | 1989 | 166 | 0.010 |
Why?
|
| Los Angeles | 1 | 1989 | 245 | 0.010 |
Why?
|
| Homosexuality | 1 | 1989 | 269 | 0.000 |
Why?
|
| Memory | 1 | 1998 | 2208 | 0.000 |
Why?
|
| Health Behavior | 1 | 2000 | 2650 | 0.000 |
Why?
|
| Prefrontal Cortex | 1 | 1999 | 2238 | 0.000 |
Why?
|
| Attention | 1 | 1998 | 2424 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1991 | 1703 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2003 | 19015 | 0.000 |
Why?
|
| Homosexuality, Male | 1 | 1995 | 1344 | 0.000 |
Why?
|
| New York City | 1 | 1989 | 737 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1993 | 2357 | 0.000 |
Why?
|
| Parent-Child Relations | 1 | 1991 | 772 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1991 | 5027 | 0.000 |
Why?
|